The Gut-Brain Axis Code: How Gut Microbiota Dysbiosis "Remotely Influences" Alzheimer's Disease - Pathological Links and Intervention Prospects
1. Introduction: A New Focus in Alzheimer's Disease and Gut-Brain Axis Research
Alzheimer's disease, a common neurodegenerative disorder, is characterized by pathological features including senile plaques formed by β-amyloid protein deposits in the brain and neurofibrillary tangles caused by hyperphosphorylation of tau protein. Despite ongoing research, its exact etiology remains incompletely understood, and effective prevention and treatment methods are still lacking. In recent years, with the rise of the "gut-brain axis" concept, the role of gut microbiota in the onset and progression of Alzheimer's disease has gained increasing attention. Related research provides new directions for exploring the mechanisms of this disease.
2. Alterations in Gut Microbiota Structure and Function in Alzheimer's Patients
Recent clinical studies have found significant differences in gut microbiota composition between Alzheimer's patients and healthy controls. Specific manifestations include:
Reduced Microbiota Diversity: The richness and evenness of gut microorganisms in patients are noticeably lower.
Changes at the Phylum Level: The relative abundance of beneficial phyla such as Firmicutes and Actinobacteria decreases, while the proportion of potentially pathogenic phyla like Bacteroidetes increases.
Dysfunctional Metabolic Pathways: Biological functions involving the microbiota, such as metabolism, signal transduction, and bacterial motility, become disrupted.
These structural and functional changes formally categorize Alzheimer's disease within the spectrum of disorders associated with gut microbiota dysbiosis.
3. Potential Mechanisms Linking Key Microbiota Shifts to Alzheimer's Pathogenesis
1. Reduction in Firmicutes and Association with Metabolic Disorders
A decrease in the Firmicutes phylum has also been reported in populations with type 2 diabetes and obesity. Diabetes and insulin resistance are known significant risk factors for Alzheimer's disease, with mechanisms potentially linked to decreased cerebral glucose metabolism and increased amyloid deposition. Therefore, gut microbiota may indirectly promote the pathological progression of Alzheimer's by influencing host metabolism.
2. Increase in Bacteroidetes and Neuroinflammatory Mechanisms
Bacteroidetes are Gram-negative bacteria whose cell wall component, lipopolysaccharide (LPS), has potent pro-inflammatory effects. Research indicates:
LPS can promote the fibrillization of β-amyloid protein in vitro.
LPS injection in animal experiments exacerbates amyloid plaque deposition in the brain.
LPS co-localization with amyloid plaques has been found in post-mortem brain tissue of Alzheimer's patients.
With aging, increased intestinal permeability combined with elevated Bacteroidetes may promote LPS entry into the bloodstream, triggering systemic inflammation and thereby accelerating neuropathology.
3. Reduction in Bifidobacterium and Impaired Barrier Function
Bifidobacterium, as a beneficial bacterium, has anti-inflammatory effects, enhances the intestinal mucosal barrier, and reduces blood LPS levels. Studies have found:
Bifidobacterium is significantly reduced in the gut of Alzheimer's patients.
Its decrease, combined with the increase in Bacteroidetes, forms a "pro-inflammatory microbiota structure," exacerbating bacterial and toxin translocation.
Small-scale clinical trials show that supplementing with probiotics containing Bifidobacterium can improve cognitive scores in patients.
4. Supporting Evidence from Animal Models and Prospective Studies
In transgenic mouse models of Alzheimer's disease, germ-free mice exhibited significantly less cerebral amyloid deposition compared to conventionally raised mice, suggesting that gut microbiota regulates protein aggregation. Furthermore, in elderly individuals with cognitive impairment but no formal diagnosis, positron emission tomography (PET) scans showed that those positive for amyloid protein had increased levels of pro-inflammatory bacteria (such as Escherichia and Shigella) and decreased levels of anti-inflammatory bacteria (such as Eubacterium rectale) in their gut. This further supports the involvement of the microbiota-brain axis in the early stages of the disease.
5. Conclusion and Outlook: Towards Microbiome-Targeted Intervention Strategies
Current evidence indicates that structural and functional dysbiosis of the gut microbiota is closely related to the onset and progression of Alzheimer's disease. Future efforts should utilize animal models and human longitudinal studies to establish causality and further explore:
The mechanisms of action of microbiota-regulated metabolites (such as short-chain fatty acids and LPS).
The efficacy of microbial intervention strategies like probiotics, prebiotics, or microbiota transplantation.
The development of early diagnostic biomarkers based on the gut-brain axis.
Restoring a healthy microbiota structure or utilizing beneficial microbial metabolites may open new therapeutic avenues for the prevention and treatment of Alzheimer's disease.
This article is curated from external sources and published by CHN Healthcare Network. The views expressed do not necessarily reflect the platform’s position. For copyright concerns regarding content or images, please contact us at info@healthcarechn.com for prompt resolution.